Search research articles
Contact Us
Filters
Showing results (71-80 of 129) with videos related to
Page
of 13
Sort By:
Journal of the National Cancer Institute
|
July 6, 1988
Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity
E K Rowinsky, D A Noe, D W Orr, et al.
Cancer Research
|
August 15, 1989
Phase I and pharmacodynamic study of taxol in refractory acute leukemias
E K Rowinsky, P J Burke, J E Karp, et al.
Blood
|
January 1, 1989
In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia
J E Karp, R C Donehower, J P Enterline, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1995
Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia
W J Slichenmyer, R C Donehower, T L Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1986
Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer
E K Rowinsky, D S Ettinger, L B Grochow, et al.
Cancer Chemotherapy and Pharmacology
|
October 11, 2001
Bioavailability of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine
S O'Reilly, N R Hartman, K M Bowling, et al.
Journal of the National Cancer Institute. Monographs
|
January 1, 1993
Hepatic metabolism and biliary excretion of Taxol in rats and humans
B Monsarrat, P Alvinerie, M Wright, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1994
Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data
J M Borkowski, M Duerr, R C Donehower, et al.
Journal of the National Cancer Institute
|
June 5, 1996
Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines
S H Kaufmann, D Peereboom, C A Buckwalter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1996
Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors
E K Rowinsky, L B Grochow, S E Sartorius, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 129) with videos related to
Sort By:
Page
of 13
Journal of the National Cancer Institute
|
July 6, 1988
Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity
E K Rowinsky, D A Noe, D W Orr, et al.
Cancer Research
|
August 15, 1989
Phase I and pharmacodynamic study of taxol in refractory acute leukemias
E K Rowinsky, P J Burke, J E Karp, et al.
Blood
|
January 1, 1989
In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia
J E Karp, R C Donehower, J P Enterline, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1995
Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia
W J Slichenmyer, R C Donehower, T L Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1986
Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer
E K Rowinsky, D S Ettinger, L B Grochow, et al.
Cancer Chemotherapy and Pharmacology
|
October 11, 2001
Bioavailability of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine
S O'Reilly, N R Hartman, K M Bowling, et al.
Journal of the National Cancer Institute. Monographs
|
January 1, 1993
Hepatic metabolism and biliary excretion of Taxol in rats and humans
B Monsarrat, P Alvinerie, M Wright, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1994
Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data
J M Borkowski, M Duerr, R C Donehower, et al.
Journal of the National Cancer Institute
|
June 5, 1996
Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines
S H Kaufmann, D Peereboom, C A Buckwalter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1996
Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors
E K Rowinsky, L B Grochow, S E Sartorius, et al.
Page
of 13